Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Deliver mOre aPplications for More Durable Pulmonary Vein IsOlation

Pulmonary vein isolation (PVI) by catheter ablation (CA) has become a widely accepted interventional treatment for patients with symptomatic atrial fibrillation (AF) despite anti-arrhythmic drugs (AAD). Classic thermal ablation modalities use radiofrequency energy or cryo-energy to create cardiac tissue lesions. Irreversible electroporation (IRE) using pulsed field energy (PFA) is a novel technology for cardiac tissue ablation. Initial studies have shown favorable outcome data in patients with AF treated by performing PVI using PFA. However, the freedom of AF has not yet proven superior to existing thermal ablation methods and appears similarly associated with suboptimal lesion durability, leading to electrical reconnection. The purpose of this study is to determine if freedom of atrial fibrillation may be improved by delivering more and better targeted pulsed field ablations.

Participants needed: 378
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: R&D CardiologieUpdated: Jun 30, 2026Locations: 1
Eligibility criteria

Be scheduled for PVI with the use of the FARAPULSE catheter ablation system AND [+2]

Cerebrovascular accident (CVA) in the last 6 months [+11]

Status: Recruiting

Evaluation of Ablation Lesions Using Cardiovascular Magnetic Resonance Imaging

Ineffective ablation lesions can cause arrhythmia recurrence after catheter ablation for cardiac arrhythmia. Ablation lesions can be created with various ablation energy modalities. This study uses cardiovascular magnetic resonance imaging to evaluate the ablation lesion characteristics of radiofrequency ablation, ultra-low temperature cryo ablation, and pulsed field ablation. The ablation lesion characteristics of different energy characteristics will be compared. Additionally, arrhythmia recurrence and quality of life will be evaluated for the different energy modalities.

Participants needed: 60
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: R&D CardiologieUpdated: Jul 28, 2025Locations: 1
Eligibility criteria

Adult patients (age ≥18 years old) [+2]

Known (or suspected) allergic reaction to gadolinium [+3]